RES 529

Drug Profile

RES 529

Alternative Names: P 529; P 52901; Palomid 529; Palomids; RES-529; SG-00529

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Paloma Pharmaceuticals
  • Developer Diffusion Pharmaceuticals; National Cancer Institute (USA)
  • Class Antiepileptic drugs; Antifibrotics; Antineoplastics; Antipsoriatics; Chromans; Eye disorder therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Hypoxia-inducible factor 1 inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Proto oncogene protein c-akt inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Age-related macular degeneration
  • Preclinical Atopic dermatitis; Breast cancer; Cancer; Diabetic retinopathy; Epilepsy; Glioblastoma; Proliferative vitreoretinopathy; Prostate cancer; Psoriasis; Scars
  • Research Pulmonary fibrosis; Rosacea

Most Recent Events

  • 15 Apr 2016 Phase-I development is ongoing for Age-related macular degeneration in USA
  • 15 Mar 2016 Preclinical trials in Breast cancer in USA (PO)
  • 15 Mar 2016 Preclinical trials in Glioblastoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top